MNOV - MediciNova Inc Stock Price, Fair Value and News

$1.50+0.03 (+2.04%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MNOV Price Action

Last 7 days

3.5%

Last 90 days

11.9%

Trailing 12 Months

-34.8%

MNOV RSI Chart

MNOV Valuation

Market Cap

73.6M

Price/Earnings (Trailing)

-6.13

Price/Sales (Trailing)

62.64

EV/EBITDA

-4.03

Price/Free Cashflow

-7.92

MNOV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MNOV Fundamentals

MNOV Revenue

Revenue (TTM)

1.2M

Rev. Growth (Yr)

-72.46%

Rev. Growth (Qtr)

-62.05%

MNOV Earnings

Earnings (TTM)

-12.0M

Earnings Growth (Yr)

-6.95%

Earnings Growth (Qtr)

7.03%

MNOV Profitability

Operating Margin

100.00%

EBT Margin

-940.33%

Return on Equity

-27.32%

Return on Assets

-25.24%

Free Cashflow Yield

-12.63%

MNOV Investor Care

Diluted EPS (TTM)

-0.25

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	1.6M	1.5M	1.4M	0
2024	2.7M	2.7M	2.1M	1.7M
2023	1.3M	1.6M	2.4M	2.8M
2022	3.2M	2.4M	1.6M	809.7K
2021	7.4M	8.7M	9.9M	4.0M
2020	6.6M	7.0M	6.6M	6.2M
2019	1.7M	1.7M	1.8M	6.5M
2018	7.8M	5.7M	3.6M	1.5M
2017	2.6M	5.0M	7.5M	9.9M
2016	495.5K	383.5K	271.5K	159.5K
2015	2.9M	2.1M	1.4M	607.5K
2014	5.4M	4.8M	4.3M	3.7M
2013	3.4M	0	0	6.0M
2012	0	0	0	802.6K

Get all data in R, Python etc through our Historical Stock Data APIs

About MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

CEO	Dr. Yuichi Iwaki M.D., Ph.D.
WEBSITE	medicinova.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	13

MediciNova Inc Frequently Asked Questions

What is the ticker symbol for MediciNova Inc? What does MNOV stand for in stocks?

MNOV is the stock ticker symbol of MediciNova Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MediciNova Inc (MNOV)?

As of Wed Dec 03 2025, market cap of MediciNova Inc is 73.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MNOV stock?

You can check MNOV's fair value in chart for subscribers.

Is MediciNova Inc a good stock to buy?

The fair value guage provides a quick view whether MNOV is over valued or under valued. Whether MediciNova Inc is cheap or expensive depends on the assumptions which impact MediciNova Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNOV.

What is MediciNova Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, MNOV's PE ratio (Price to Earnings) is -6.13 and Price to Sales (PS) ratio is 62.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MNOV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MediciNova Inc's stock?

In the past 10 years, MediciNova Inc has provided -0.075 (multiply by 100 for percentage) rate of return.